Literature DB >> 19546160

Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.

Roland Kaufmann1, Claudia Oettel, Antje Horn, Karl-Jürgen Halbhuber, Annett Eitner, Reimar Krieg, Kathrin Katenkamp, Peter Henklein, Martin Westermann, Frank D Böhmer, Rithwik Ramachandran, Mahmoud Saifeddine, Morley D Hollenberg, Utz Settmacher.   

Abstract

The expression of proteinase-activated receptor (PAR)(2) in human hepatocellular carcinoma (HCC) was established by reverse transcription-polymerase chain reaction, confocal immunofluorescence and electron microscopy in permanent cell lines, primary HCC cell cultures and HCC tumor tissue. Stimulation of HCC cells with trypsin and the PAR(2)-selective activating peptide, 2-furoyl-LIGRLO-NH(2), increased cell invasion across Matrigel. Both effects were blocked by a PAR(2)-selective pepducin antagonist peptide (pal-PAR(2)) and by PAR(2) silencing with specific small interfering RNA (siRNA). PAR(2)-initiated HCC cell invasion was also blocked by inhibiting the hepatocyte growth factor receptor (Met receptor tyrosine kinase) with the receptor-targeted kinase inhibitors, SU 11274 and PHA 665752, or by downregulation of Met with specific siRNA. The involvement of Met in PAR(2)-mediated HCC invasive signaling was further supported by the finding that treatment of HCC cells with trypsin or the PAR(2)-selective agonist peptide, 2-furoyl-LIGRLO-NH(2), stimulated Met activation-phosphorylation. In addition, Met-dependent stimulation of p42/p44 mitogen-activated protein Kinases was found to be critical for the PAR(2)-Met receptor tyrosine kinase-invasive signaling axis in HCC cells. Our study establishes an important link between the PAR(2) and Met receptor tyrosine kinase signaling in promoting HCC cell invasion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546160     DOI: 10.1093/carcin/bgp153

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  23 in total

Review 1.  Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development.

Authors:  Katie O'Callaghan; Athan Kuliopulos; Lidija Covic
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

Review 2.  Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.

Authors:  Sarah L Tressel; Georgios Koukos; Boris Tchernychev; Suzanne L Jacques; Lidija Covic; Athan Kuliopulos
Journal:  Methods Mol Biol       Date:  2011

3.  Proteinase-activated receptor 2-mediated calcium signaling in hepatocellular carcinoma cells.

Authors:  Roland Kaufmann; Franziska Mussbach; Petra Henklein; Utz Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-02       Impact factor: 4.553

4.  Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level.

Authors:  Roland Kaufmann; Alexander Hascher; Franziska Mussbach; Petra Henklein; Kathrin Katenkamp; Martin Westermann; Utz Settmacher
Journal:  Histochem Cell Biol       Date:  2012-08-15       Impact factor: 4.304

Review 5.  Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression.

Authors:  Nisha R Pawar; Marguerite S Buzza; Toni M Antalis
Journal:  Cancer Res       Date:  2019-01-04       Impact factor: 12.701

6.  Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation.

Authors:  Franziska Mußbach; Petra Henklein; Martin Westermann; Utz Settmacher; Frank-D Böhmer; Roland Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-06       Impact factor: 4.553

7.  Evaluation of antibodies directed against human protease-activated receptor-2.

Authors:  Mark N Adams; Charles N Pagel; Eleanor J Mackie; John D Hooper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-31       Impact factor: 3.000

8.  TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620.

Authors:  Lichao Hu; Longfei Xia; Hong Zhou; Biao Wu; Yuan Mu; Ying Wu; Jinchuan Yan
Journal:  Tumour Biol       Date:  2013-04-25

9.  Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein.

Authors:  Julie Quoyer; Jay M Janz; Jiansong Luo; Yong Ren; Sylvain Armando; Viktoria Lukashova; Jeffrey L Benovic; Kenneth E Carlson; Stephen W Hunt; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-05       Impact factor: 11.205

10.  The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy.

Authors:  Ming-Chao Tsai; Chih-Che Lin; Ding-Wei Chen; Yueh-Wei Liu; Yi-Ju Wu; Yi-Hao Yen; Pao-Yuan Huang; Chih-Chien Yao; Ching-Hui Chuang; Chang-Chun Hsiao
Journal:  Medicina (Kaunas)       Date:  2021-06-04       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.